BioSpace News Archive

Evelo Biosciences, along with Rutgers University and Robert Wood Johnson University Hospital, is driving toward a Phase II study of an investigational treatment for hospitalized patients with newly diagnosed COVID-19.

San Francisco-based life sciences real estate development firm IQHQ completed the acquisition of a South San Francisco site known as South City Station.

The race has been ongoing to develop an approved therapy for nonalcoholic steatohepatitis (NASH) and Axcella is moving closer to the goal line following positive topline data from a clinical study dubbed AXA1125-003.

The actual death toll for COVID-19 won’t be calculable for some time, but there are early indications that it may be significantly lower than calculations of deaths per confirmed cases lead one to believe.

Pharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

As the world continues to grapple with the effects of the COVID-19 pandemic, healthcare analysts are starting to wonder how the outbreak will impact drug development.

Ansun Pharmaceuticals used its influenza research data to dive into attempts to develop a treatment for COVID-19. DAS181 is it’s potential candidate for COVID-19.

“It is the right time to have an excellent fully integrated, patient-focused biotechnology organization like PTC Therapeutics take over the late-stage development of CNSA-001 so that this promising compound becomes available to patients in the near future,” said Jonathan Reis, president and chief executive officer of Censa.

What change can you make to stay positive during these uncertain times?

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.